Drugs / pNGVL4a-Sig/E7(detox)/HSP70
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06508138 Comparator | Oct 2023 → Apr 2027 expected | human papilloma virus infection, human papillomavirus-related squamous cell carcinoma, metastatic malignant neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pNGVL4a-Sig/E7(detox)/HSP70 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06508138 ↗ |
| Modality | Vaccine | “The first two shots the participant would be given are a vaccine called "pNGVL4a-Sig/E7 (detox)/HSP70", and it contains DNA, the blueprint for making proteins.” NCT06508138 ↗ |
| Route | Intramuscular | “This vaccine is given as a shot into a muscle either in the shoulder or in the thigh.” NCT06508138 ↗ |